FDA Accepts Galderma’s BLA Resubmission for RelabotulinumtoxinA
The agency has accepted the resubmission seeking approval of the neuromodulator for the temporary improvement of moderate-to-severe glabellar lines and crow’s feet in adults.
The agency has accepted the resubmission seeking approval of the neuromodulator for the temporary improvement of moderate-to-severe glabellar lines and crow’s feet in adults.
